房颤擅自停服这种药,危及生命

2017-10-17 高娟 北京青年报

68岁的高阿姨从前年开始,经常感到“心慌”,到医院做了心电图后被确诊为“心房颤动”,也就是通俗说的“房颤”。

不遵医嘱发生紧急状况

68岁的高阿姨从前年开始,经常感到“心慌”,到医院做了心电图后被确诊为“心房颤动”,也就是通俗说的“房颤”。

医生说房颤患者首先要预防中风,于是给高阿姨开了预防中风的抗凝药和其他治疗房颤的药。过了一段时间,高阿姨觉得吃那么多药太麻烦,经常吃了上顿忘了下顿,而且抗凝药只是起预防作用,怀着侥幸心理的她就把抗凝药给停了。可谁知,前几天麻将席上,高阿姨突然嘴歪眼斜,一头栽倒在地,人事不省。好在及时送到医院进行了抢救。现在半身不遂坐在轮椅上的高阿姨后悔不已。医生说,这恰是擅自停药害了她。

中国医学科学院阜外医院心律失常中心副主任、二病区主任姚焰主任再次强调:“许多房颤患者需要终身服用抗凝药来预防中风,如果不遵医嘱擅自停药,中风就很有可能会找上门。”

哪些房颤患者需要长期抗凝?

姚焰主任表示,“无论是阵发性房颤还是持久性房颤,都能导致中风。”

房颤患者如何判断自己是否有中风风险?欧洲心脏病协会(ESC)心房颤动处理指南(2010年版)提出了CHA2DS2-VASc评分系统。评估的总分值是9分,其中,充血性心力衰竭/左心功能不全、高血压糖尿病血管病变、年龄65~74岁、女性各占1分;先前曾有中风或短暂性脑缺血发作或全身性栓塞、年龄≥75岁各占2分。得分越高,中风的风险也就越大。

姚焰主任指出:“如果危险因素分值在2分或以上,则需要进行抗凝治疗。如果疏于抗凝,房颤患者将面临高于常人五倍的中风风险。”有研究显示,房颤引发的中风30天内的死亡率可达25%,一年内死亡率则高达50%。

坚持正确抗凝,不让房颤钻空子

除了像高阿姨这样因为不坚持抗凝而中风的,还有不少房颤病人坚持用阿司匹林,最后还是中风了。这是怎么回事?

姚焰主任解释:“这是‘武器’没选对。阿司匹林是抗血小板药,而房颤导致的血栓主要是凝血因子在起作用,阿司匹林的预防效果几乎没有。房颤患者抗凝应该选择达比加群酯等新型口服抗凝药或华法林。”

过去常用的传统抗凝药是华法林,但由于剂量个体差异大,再加上中国人食物结构比西方人复杂,存在较多的食物、药物相互作用,患者还需要频繁去医院抽血监测,实在不易坚持。

近几年上市的新型口服抗凝药物,避免了传统药物的诸多问题,无需调整剂量和验血监测,服用方便且安全性更高。今年这类新型口服抗凝药已经进入国家医保目录,现已纳入到我市门诊医保报销范围。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=256656, encodeId=52942566564c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Sat Oct 28 11:44:10 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253669, encodeId=7393253669fe, content=阅读.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Tue Oct 17 08:53:52 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253664, encodeId=827d25366467, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Tue Oct 17 08:50:44 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253652, encodeId=f760253652f1, content=很好很好很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/07/8c1e5a0085f3b74f3a4ab58a38a3d487.jpg, createdBy=b33e2159612, createdName=2227437833_79976374, createdTime=Tue Oct 17 08:19:33 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253612, encodeId=f6d3253612da, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Tue Oct 17 06:57:26 CST 2017, time=2017-10-17, status=1, ipAttribution=)]
    2017-10-28 yfjms

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=256656, encodeId=52942566564c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Sat Oct 28 11:44:10 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253669, encodeId=7393253669fe, content=阅读.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Tue Oct 17 08:53:52 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253664, encodeId=827d25366467, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Tue Oct 17 08:50:44 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253652, encodeId=f760253652f1, content=很好很好很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/07/8c1e5a0085f3b74f3a4ab58a38a3d487.jpg, createdBy=b33e2159612, createdName=2227437833_79976374, createdTime=Tue Oct 17 08:19:33 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253612, encodeId=f6d3253612da, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Tue Oct 17 06:57:26 CST 2017, time=2017-10-17, status=1, ipAttribution=)]
    2017-10-17 刘煜

    阅读.谢谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=256656, encodeId=52942566564c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Sat Oct 28 11:44:10 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253669, encodeId=7393253669fe, content=阅读.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Tue Oct 17 08:53:52 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253664, encodeId=827d25366467, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Tue Oct 17 08:50:44 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253652, encodeId=f760253652f1, content=很好很好很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/07/8c1e5a0085f3b74f3a4ab58a38a3d487.jpg, createdBy=b33e2159612, createdName=2227437833_79976374, createdTime=Tue Oct 17 08:19:33 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253612, encodeId=f6d3253612da, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Tue Oct 17 06:57:26 CST 2017, time=2017-10-17, status=1, ipAttribution=)]
    2017-10-17 Y—xianghai

    学习了新知识

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=256656, encodeId=52942566564c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Sat Oct 28 11:44:10 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253669, encodeId=7393253669fe, content=阅读.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Tue Oct 17 08:53:52 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253664, encodeId=827d25366467, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Tue Oct 17 08:50:44 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253652, encodeId=f760253652f1, content=很好很好很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/07/8c1e5a0085f3b74f3a4ab58a38a3d487.jpg, createdBy=b33e2159612, createdName=2227437833_79976374, createdTime=Tue Oct 17 08:19:33 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253612, encodeId=f6d3253612da, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Tue Oct 17 06:57:26 CST 2017, time=2017-10-17, status=1, ipAttribution=)]
    2017-10-17 2227437833_79976374

    很好很好很好

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=256656, encodeId=52942566564c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Sat Oct 28 11:44:10 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253669, encodeId=7393253669fe, content=阅读.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Tue Oct 17 08:53:52 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253664, encodeId=827d25366467, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Tue Oct 17 08:50:44 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253652, encodeId=f760253652f1, content=很好很好很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/07/8c1e5a0085f3b74f3a4ab58a38a3d487.jpg, createdBy=b33e2159612, createdName=2227437833_79976374, createdTime=Tue Oct 17 08:19:33 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253612, encodeId=f6d3253612da, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Tue Oct 17 06:57:26 CST 2017, time=2017-10-17, status=1, ipAttribution=)]
    2017-10-17 明月清辉

    谢谢分享.学习了

    0

相关资讯

这大概是他最后一次血栓栓塞了吧……

虽然房颤很普遍,连国内大型流行病学调查显示,其患病率接近百分之一,减少血栓栓塞并发症是重要的目标,故抗凝是房颤治疗的重要内容。但要在国内目前的医疗现状下做好这项工作,难度相当大。

HEART:绝经与房颤有关么?

目前,关于绝经和心房颤动(AF)之间相关性的研究数据十分有限。近期,一项发表在杂志Heart上的研究评估了绝经年龄、绝经后激素治疗(PHT)和事件性房颤之间的关系。此项研究招募了在1992年至1995年期间39876名女性保健专业人员。研究者们使用Cox比例风险模型检查了女性健康研究(WHS)中的30034名受试者。参与者在基线时无心血管疾病和房颤,在绝经前没有接受子宫切除术,无双侧卵巢切除术。事

房颤导管消融并发症的识别与处理

近年来,随着医疗技术的不断改善,房颤导管消融并发症呈下降趋势,2009年一项全球调查数据显示,房颤导管消融并发症的发生率为4.5%。 在第二十八届长城国际心脏病学会议中,来自首都医科大学附属北京朝阳医院的刘兴鹏教授带来了《房颤导管消融并发症的识别与处理》的精彩讲课,重点讲解了心肌穿孔/心脏压塞、肺静脉狭窄、脑卒中、心房食管瘘等房颤导管消融术的主要并发症,以下是小编整理的重点内容,分享给大家。

CHEST:亚洲人群房颤的终身风险、预计数量和不良结局!

目前,关于房颤(AF)临床流行病学的大部分数据来自西方人群,有关亚洲人群的数据十分有限。近期,一项发表在杂志CHEST上的研究调查了亚洲人AF的终身风险和预计数量,并分析了与非AF患者相比,AF患者不良事件的年度风险和时间趋势。此项研究从2000年开始到2011年,共招募了289,559例年龄≥20岁的台湾新发AF患者。计算受试者房颤的发生率、患病率和终生风险。对AF患者的不良事件风险进行分析,并

房颤患者围手术期,抗栓治疗可不简单!

心房颤动(AF)是最常见的心血管疾病之一,这类人群在围手术期可能会面对两类血栓栓塞风险,一类是AF相关缺血性卒中,一类是围术期相关静脉血栓栓塞症(VTE)。更令人头疼的是,存在栓塞风险就可能伴随出血风险,这使得心内科医师要熟练掌握围术期的抗栓策略。

JACC:房颤致左室收缩功能不全尚未得到充分重视

房颤和左室收缩功能不全(LVSD)常合并出现。近日,在国际心血管权威杂志JACC上发表了一篇旨在评估比较导管消融治疗和药物治疗房颤对左室收缩功能不全影响的临床研究。本次多中心随机对照临床研究纳入了持续性房颤伴特发性心肌病(左室射血分数[LVEF]≤45%)的患者。患者在随机分成导管消融治疗组和药物控制组之前,接受了心脏增强磁共振检查,以评估是否存在室壁纤维瘤。导管消融包括肺静脉隔离治疗和后壁静脉隔